Genmab — M&A Activity 2017

Jan 6, 2017

Company Announcement

-- First sales volume milestone reached in DARZALEX (daratumumab)
collaboration with Janssen
-- Genmab to receive milestone payment of USD 25 million

Copenhagen, Denmark; January 6, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN)
announced today that it has achieved the first sales volume milestone in its
DARZALEX® (daratumumab) collaboration with Janssen. The USD 25 million
milestone was triggered by sales of DARZALEX reaching USD 500 million in a
calendar year. In August 2012, Genmab granted Janssen Biotech, Inc. an
exclusive worldwide license to develop, manufacture and commercialize DARZALEX.

“We have seen an extremely robust launch of DARZALEX since its approval in the
U.S in November 2015 and in Europe in May 2016, with very rapid sales uptake.
We are very pleased to receive the first commercial sales volume milestone so
quickly,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The milestone payment was included in Genmab’s financial guidance published on
December 20, 2016.

About DARZALEX® (daratumumab)
DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the
United States in combination with lenalidomide and dexamethasone, or bortezomib
and dexamethasone, for the treatment of patients with multiple myeloma who have
received at least one prior therapy and as a monotherapy for the treatment of
patients with multiple myeloma who have received at least three prior lines of
therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent,
or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX
is the first monoclonal antibody (mAb) to receive U.S. Food and Drug
Administration (FDA) approval to treat multiple myeloma. DARZALEX is indicated
in Europe for use as monotherapy for the treatment of adult patients with
relapsed and refractory multiple myeloma, whose prior therapy included a PI and
an immunomodulatory agent and who have demonstrated disease progression on the
last therapy. For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high
affinity to the CD38 molecule, which is highly expressed on the surface of
multiple myeloma cells. Daratumumab triggers a person’s own immune system to
attack the cancer cells, resulting in rapid tumor cell death through multiple
immune-mediated mechanisms of action and through immunomodulatory effects, in
addition to direct tumor cell death, via apoptosis (programmed cell
death).1,2,3,4,5

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive
worldwide license to develop, manufacture and commercialize daratumumab from
Genmab. Five Phase III clinical studies with daratumumab in relapsed and
frontline multiple myeloma settings are currently ongoing, and additional
studies are ongoing or planned to assess its potential in other malignant and
pre-malignant diseases on which CD38 is expressed, such as smoldering myeloma,
non-Hodgkin’s lymphoma, NKT-cell lymphoma, amyloidosis, Myelodysplastic
Syndromes and solid tumors. Daratumumab has received two Breakthrough Therapy
Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and
in combination with other therapies.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
DARZALEX® (daratumumab) for the treatment of certain multiple myeloma
indications, and Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications. Daratumumab is in clinical development for
additional multiple myeloma indications, non-Hodgkin’s lymphoma and solid
tumors. A subcutaneous formulation of ofatumumab is in development for
relapsing multiple sclerosis. Genmab also has a broad clinical and
pre-clinical product pipeline. Genmab's technology base consists of validated
and proprietary next generation antibody technologies - the DuoBody® platform
for generation of bispecific antibodies, and the HexaBody® platform which
creates effector function enhanced antibodies. The company intends to leverage
these technologies to create opportunities for full or co-ownership of future
products. Genmab has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

1 FDA 2015. Daratumumab Prescribing information. Available at:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig1s000lbledt.p
df.
Last accessed December 2016.

2 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal
Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors.
The Journal of Immunology. 2011; 186: 1840-1848.
3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the
anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and
multiple myeloma. MAbs. 2015; 7: 311-21.
4 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells,
Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma.
Blood. 2016; 128: 384-94.
5 Jansen, JH et al. Daratumumab, a human CD38 antibody induces apoptosis of
myeloma tumor cells via Fc receptor-mediated crosslinking. Blood.
2012;120(21):abstract 2974.

Company Announcement no. 01
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark